Pelareorep (Reolysin) has been evaluated—alone or with GM-CSF or radio/chemotherapy—in GBM; to date, reports highlight safety without clear efficacy gains, necessitating larger trials [4,11]. The gene discussed is CSF2; the disease is glioblastoma.